Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mild to Moderate Atopic Dermatitis Clear all

Conditions: Atopic Dermatitis
Interventions: DMT210 Topical Gel, Vehicle Control; Drug
Lead sponsor: Dermata Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Houston, Texas • Norfolk, Virginia

Conditions: Mild to Moderate Atopic Dermatitis
Interventions: HL-009 Liposomal Gel, Placebo; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Arlington Heights, Illinois • Fridley, Minnesota • Berlin, New Jersey + 4 more

Conditions: Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions: PF-06817024, Placebo for PF-06817024; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more

Conditions: Atopic Dermatitis Eczema
Interventions: AO+Mist, Placebo; Other
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis Eczema
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Atopic Dermatitis
Interventions: FB-401, Placebo; Biological
Lead sponsor: Forte Biosciences, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Fountain Valley, California • Fremont, California • Lake City, Florida + 12 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 200 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Novartis Pharmaceuticals, New Jersey

Conditions: Atopic Dermatitis, Pruritus
Interventions: RD047-26; Device
Lead sponsor: Oculus Innovative Sciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Atopic Dermatitis
Interventions: Difamilast; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Contact Dermatitis, Eczema, Contact
Interventions: Epikeia Coatings; Device
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Atopic Dermatitis
Interventions: Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream; Drug · Device
Lead sponsor: Ceragenix Pharmaceuticals; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: San Diego, California • Portland, Oregon

Conditions: Dermatitis, Atopic
Interventions: VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P; Drug · Other
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more

Conditions: Atopic Dermatitis
Interventions: PRN473 (SAR444727), Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Long Beach, California • Los Angeles, California • Miami, Florida + 6 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Interventions: HY209GEL Active, Placebo; Drug · Other
Lead sponsor: Shaperon; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 4 more

Conditions: Atopic Dermatitis
Interventions: 50 mg S-777469, 200 mg S-777469, 800 mg S-777469, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Atopic Dermatitis
Interventions: FB-401; Biological
Lead sponsor: Forte Biosciences, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 8
States / cities: Fremont, California • Lake City, Florida • Newnan, Georgia + 5 more

Conditions: Atopic Dermatitis Eczema
Interventions: Arctiva; Other
Lead sponsor: ClinOhio Research Services, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dermatitis, Atopic
Interventions: Wash IP, Cream IP; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 3 Months to 72 Months
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: High Point, North Carolina • Lynchburg, Virginia

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment, Vehicle ointment; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more

Conditions: Dermatitis, Atopic, Pruritus
Interventions: ASN008, ASN008 Matching Vehicle; Drug · Other
Lead sponsor: Formation Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more

Conditions: Atopic Dermatitis (AD)
Interventions: Experimental Product; Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 6 Months and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: St. Petersburg, Florida • Fair Lawn, New Jersey

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 90 Years
Enrollment: 587 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more

Search by objective public record fields.

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Novel Topical Treatment of Hand Dermatitis (Eczema)

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis